News Search Results
Aug 06, 2025, 12:16 ET Clara Jensen Joins Rubin and Rudman's Trusts and Estates Group
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Aug 06, 2025, 11:12 ET Advanced In Vivo Efficacy Models for Preclinical Success, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 06, 2025, 10:45 ET Biomarkers Market to Grow at a CAGR of 12.3% from 2025 to 2032 | SkyQuest Technology Consulting
treatment plans to individual genetic profiles, improving efficacy and minimizing side effects.By end user, pharmaceutical and biotechnology companies dominate since they invest heavily in biomarker development to accelerate drug discovery, clinical trials, and market approvals.Buy
More news about: SkyQuest Technology
Aug 06, 2025, 10:29 ET Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
masses in India. Intas' biosimilars are manufactured at Intas Pharmaceuticals' European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit
More news about: Intas Pharmaceuticals Ltd
Aug 06, 2025, 10:01 ET Pharmaceutical Suppositories Market is expected to generate a revenue of USD 2.74 Billion by 2032, Globally, at 5.91% CAGR: Verified Market Research®
(Genomics, Transcriptomics, Proteomics, Metabolomics), By Deployment Mode (Public Cloud, Private Cloud, Hybrid Cloud), By End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Hospitals and Clinics), By Geography, And Forecast
More news about: Verified Market Research
Aug 06, 2025, 10:01 ET New Report Forecasts $1.8B Helicopter Hoists Winches and Hooks Market by 2031, Fueled by EMS and Aerial Firefighting | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 06, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG
[Click here for information about joining the class action] PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
More news about: Pomerantz LLP
Aug 06, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers - DDD
Medicine Program focuses on "the use of additive manufacturing for human organ transplantation." Since 2018, 3D Systems has partnered with the biotechnology company United Therapeutics Corporation ("United") "with a long-term goal of developing the capability to 3D print lungs that will allow patients
More news about: Pomerantz LLP
Aug 06, 2025, 08:31 ET MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
Aug. 6, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has extended to 8 weeks from 4 weeks, the 48 mg, multiple ascending
More news about: MetaVia Inc.
Aug 06, 2025, 08:30 ET AI in Bioprocessing Today -- Accelerate. Predict. Deliver., Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Honeycomb Worldwide Inc.
Aug 06, 2025, 08:00 ET Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of Directors
McNamara, P.C., the largest dedicated FDA regulatory law firm in the U.S.Experience: Over 30 years advising pharmaceutical and biotechnology companies on FDA regulatory strategy, product development, and lifecycle managementStrategic Contribution: Ms. Torrente's deep regulatory
More news about: Continuity Biosciences LLC
Aug 06, 2025, 08:00 ET Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of Directors
McNamara, P.C., the largest dedicated FDA regulatory law firm in the U.S.Experience: Over 30 years advising pharmaceutical and biotechnology companies on FDA regulatory strategy, product development, and lifecycle managementStrategic Contribution: Ms. Torrente's deep regulatory
More news about: Continuity Biosciences LLC
Aug 06, 2025, 06:59 ET Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug. 6, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial
More news about: Q32 Bio
Aug 06, 2025, 06:45 ET Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer
will make significant contributions to our growth and continued success." Ms. Stamoulis has approximately 30 years of experience in the biotechnology industry. Prior to Incyte, she was President and CFO of Unum Therapeutics and, before that role, served as Senior Vice President of Corporate Strategy
More news about: Mallinckrodt plc
Aug 06, 2025, 06:30 ET BIO-TECHNE DECLARES DIVIDEND
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues, the impact of currency
More news about: Bio-Techne Corporation
Aug 06, 2025, 06:30 ET Bio-Techne Releases Fourth Quarter Fiscal 2025 Results
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and
More news about: Bio-Techne Corporation
Aug 05, 2025, 22:43 ET From AI to Precision Medicine: Taiwan's Smart Healthcare Innovations Shine at Taiwan Expo USA 2025
screening.imedtac Co., Ltd. presents its AI mmWave monitoring radar, enabling non-contact monitoring of vital physiological data.Hukui Biotechnology Co., Ltd. demonstrates a wireless handheld ultrasound device designed for both human and veterinary applications.AI at the Forefront
More news about: TITA & TAITRA
Aug 05, 2025, 16:30 ET Bio-Techne Announces Exosome Diagnostics Divestiture
acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and
More news about: Bio-Techne Corporation
Aug 05, 2025, 16:01 ET Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug. 5, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the second quarter ended June 30,
More news about: Rigel Pharmaceuticals, Inc.
Aug 05, 2025, 16:01 ET HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Aug 05, 2025, 16:01 ET AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Aug 05, 2025, 14:00 ET JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio's DEX-G2 Blood Test For Early Detection of Gastric Cancer
often diagnosed too late for curative treatment. About Cizzle Bio Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by advancing biomarker-based blood tests, starting with early detection of lung and gastric
More news about: Cizzle Bio
Aug 05, 2025, 11:48 ET Rubin and Rudman Adds Hospitality and Retail Veteran Barry Barth as Of Counsel in its Real Estate Group
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Aug 05, 2025, 11:44 ET Cell Line and Membrane Market to Grow at 12.5% CAGR Through 2030
productivity, reduce costs, and support large-scale manufacturing, especially for biologics and vaccines. Investments by Pharmaceutical and Biotechnology Companies in Drug Development: Pharma and biotech firms are investing in biologics and personalized medicine, increasing the demand for reliable
More news about: BCC Research LLC
Aug 05, 2025, 11:29 ET New Jersey Innovation Institute Appoints Chrissy Buteas and Elisa Charters
also strengthened its role in workforce development by expanding training programs in cutting-edge fields such as AI, advanced manufacturing, and biotechnology, creating hands-on opportunities for students and professionals alike About NJII The New Jersey Innovation Institute (NJII) is a 501(c)(3)
More news about: New Jersey Innovation Institute